Clinical evaluation of eterobarb, a new anticonvulsant drug.
Two clinical investigations of a new anticonvulsant, eterobarb, N,N' dimethoxymethyl phenobarbital (DMMP), were conducted in separate geographic regions. The drug has considerable efficacy in reducing the frequency of partial seizures, with and without secondary generalization, as well as generalized tonic-clonic seizures. Sedation did not appear to be as prominent with this barbiturate as it was with phenobarbital or primidone.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011324:Primidone / Q000627:therapeutic use; D011581:Psychological Tests
D000927:Anticonvulsants; D011324:Primidone; C010451:eterobarb; D010634:Phenobarbital